High-dose melphalan and autologous hematopoietic stem cell transplantation (AHSCT) is the standard treatment strategy in Multiple Myeloma (MM) patients who are eligible for AHSCT. The recommended dose of CD34+ hematopoietic progenitor cells (HPC) for adequate engraftment is above 2 x 106/kg.. The aim of this study is to evaluate the relationship between CD34+ HPC dose and the survival in MM patients who underwent AHSCT at our tertiary care center. 271 MM patients, who underwent AHSCT between 2003-2019, were enrolled in this study. Clinical characteristic of patients, disease status pre-AHSCT, re-infused CD34+ cell doses, neutrophil and platelet engraftment days were recorded, retrospectively. The patients were divided into two groups according to whether re-infused CD 34+ HPC dose were < 5 x 106 /kg or ? 5 x 106 /kg. The groups were compared in terms of engraftment and overall survival times. The median age of all patients was 54.8 (33 - 76) years. The median CD34+ HPC dose infused was 5.94 x 106/kg (1.47 - 59.5 x 106/kg). The median follow-up period was 54 months (4-211). The median overall survival of all patients was 103 months (11-144). Median neutrophil and platelet engraftment time was 10 (8-24) and 11 (7-40) days, respectively. < 5 x 106/kg and ? 5 x 106/kg CD34+ HPC were reinfused 38,1% and 61.9% of the patients, respectively. There was a negative significant correlation between reinfused CD34+ cell level and neutrophil/platelet engraftment times (r: -0.32, p= <0.001; r: -0.27, p= <0.001, respectively). The median overall survival times were observed as 103 months (11-144) and 145 months (123-166) for patients who were administered ? 5 x 106/kg and < 5 x 106/kg of CD34+ HPC, respectively (p= 0.009). The increased amount of CD34+ autologous hematopoietic stem cell dose after high dose melphalan chemotherapy in MM patients shortens platelet and neutrophil engraftment time and increases overall survival. Early platelet engraftment and administration of CD34+ HPC count ? 5 x 106/kg can be considered as predictors of a better survival in patients.